Accelerated pathways shift the proof of clinical benefit from pre-market trials to post-marketing requirements.
To expedite access to critical therapies, regulatory frameworks are granting early market entry based on surrogate biomarkers while deferring the rigorous verification of clinical efficacy to post-marketing confirmatory trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA's decision to accept early data for uniQure's BLA demonstrates how accelerated pathways shift clinical validation to post-marketing studies.
The confirmatory study for Zynlonta's accelerated approval failed to show overall survival benefit while revealing a critical, imbalanced mortality signal.
A developer is seeking accelerated approval for a rare neurodegenerative gene therapy based on a Phase I/II package, deferring final clinical verification to a post-market study.
The regulatory system grants early market entry based on intermediate data while shifting the verification of definitive clinical efficacy to post-marketing tracking.
A second post-marketing confirmatory trial failure puts Zepzelca's accelerated approval at high risk of withdrawal by the FDA.
Tzield secured early market access based on a surrogate biomarker, leaving the definitive proof of clinical benefit to the ongoing BETA-PRESERVE confirmatory study.
The FDA's decision to accept early Phase I/II data illustrates the regulatory model of allowing accelerated market entry while deferring final confirmation to post-marketing trials.
TUDRIQEV won accelerated FDA clearance based on early tumor-shrinkage metrics, with commercial market retention dependent on verifying overall survival benefits in a confirmatory Phase 3 trial.
Moderna secured early access for seniors based on accelerated approval while agreeing to confirm real-world clinical benefit via a massive post-marketing trial.
Replimune's oncology breakthrough secured early market access based on tumor response rates, leaving the confirmation of long-term overall survival benefits to post-marketing studies.
Accelerated approval's deferred proof is being cashed in through post-marketing confirmatory trials to convert conditional status into full approval.
Vera's accelerated approval is built entirely on a short-term proteinuria biomarker, leaving the burden of proving actual clinical kidney preservation to post-marketing analyses.
The FDA granted early market access for Zenbexus by accepting a novel surrogate biomarker of complete response instead of waiting for long-term clinical outcomes.
Camizestrant's sudden confirmatory trial failure highlights the immense risk of gaining early market entry before clinical efficacy is definitively proven.
Replimune must run a large, randomized post-marketing trial to verify the real-world benefit that justified its early accelerated approval.
Zepzelca's accelerated second-line SCLC approval is threatened after its mandated Phase 3 post-marketing confirmatory trial failed to establish an overall survival benefit.
Krazati's combination had its approval withdrawn after failing to verify survival benefit in its mandatory Phase 3 post-marketing confirmatory study.
The regulatory alignment on AMT-130 relies on early clinical data while pushing the requirement for a definitive randomized trial into the post-approval stage.
BMS's Zenbexus secured accelerated approval using a surrogate cellular biomarker, deferring definitive proof of survival and progression benefits to future clinical trials.
Bayer secured immediate first-line market entry for sevabertinib through accelerated approval while conducting a randomized Phase III confirmatory study to verify the clinical benefit.
uniQure's BLA submission seeks early market access based on three-year data, leaving definitive clinical confirmation to its planned post-marketing trials.
The FDA accepted uniQure's BLA for accelerated approval based on early clinical results on the condition that definitive proof of efficacy will be established in post-marketing confirmatory studies.
Ultragenyx's rare metabolic gene therapy won early approval based on a surrogate dietary reduction, deferring long-term clinical verification to a post-marketing follow-up program.